SimianX AI LogoSimianX AI

Asset profile

rezatapopt · PMV Pharmaceuticals (PMVP)

Indication
platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation
Also known as
PC14586
CompanyPMVPPMV Pharmaceuticals

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is des…

Start live analysis of PMVPRun 8-agent AI analysis

On the calendar

Timeline

Newest first.

Oct 5, 2026
01:00 PM
PMVPPMV Pharmaceuticals

PMV Pharma plans NDA submission for rezatapopt in Q1 2027

Application submittedSEC 8-KOpen record
Oct 2, 2026
03:23 PM
PMVPPMV Pharmaceuticals

rezatapopt · NCT04585750 registry update

Trial registry changeClinicalTrials.gov
Sep 16, 2026
03:20 AM
PMVPPMV Pharmaceuticals

rezatapopt · NCT04585750 registry update

Trial registry changeClinicalTrials.gov
Aug 31, 2026
08:06 PM
PMVPPMV Pharmaceuticals

PMV Pharma: 46% ORR in ovarian cancer cohort of PYNNACLE Phase 2

Topline resultsSEC 8-KOpen record1 update
Aug 14, 2026
12:00 PM
PMVPPMV Pharmaceuticals

PMV Pharmaceuticals plans rezatapopt NDA submission Q1 2027

Application submittedSEC 8-KOpen record
May 12, 2026
12:00 PM
PMVPPMV Pharmaceuticals

PMVP: Rezatapopt granted FDA Orphan Drug Designation for TP53 Y220C ovarian cancer

FDA designationSEC 8-K
Mar 6, 2026
01:24 PM
PMVPPMV Pharmaceuticals

PMVP: rezatapopt granted FDA Orphan Drug Designation for TP53 Y220C ovarian cancer

FDA designationSEC 8-K
Nov 12, 2025
01:00 PM
PMVPPMV Pharmaceuticals

PMV Pharma: PYNNACLE Phase 2 data at AACR-NCI-EORTC 2025

Conference presentationSEC 8-K

Registered trials

Registry IDPhaseStatusPrimary completionEnrollmentSites
NCT04585750Phase 1/2RecruitingDec 15, 202630032 of 76 sites in the United States
rezatapopt · PMV Pharmaceuticals (PMVP) — FDA Timeline & Readiness Checklist | SimianX AI